

BioScrip, Inc.  
Form 8-K  
August 14, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C.**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported): August 11, 2008  
BioScrip, Inc.  
(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**0-28740**  
(Commission  
File Number)

**05-0489664**  
(IRS Employer  
Identification No.)

**100 Clearbrook Road, Elmsford, New York**  
(Address of Principal Executive Offices)

**10523**  
(Zip Code)

Registrant's telephone number, including area code **(914) 460-1600**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

**Item 2.01 Entry Into a Material Definitive Agreement.**

On August 11, 2008, BioScrip, Inc. (the Company ), through its subsidiaries BioScrip Pharmacy Services, Inc., BioScrip Infusion Services, Inc., BioScrip Pharmacy (NY), Inc., BioScrip PBM Services, LLC, BioScrip Pharmacy, Inc., Natural Living, Inc., BioScrip Infusion Services, LLC and Bradhurst Specialty Pharmacy, Inc. (collectively, the Borrowers ), entered into a Third Amendment to the Amended and Restated Loan and Security Agreement (the LSA ) among the Borrowers and HFG Healthco-4 LLC, an affiliate of Healthcare Finance Group, Inc. ( HFG ), which increased the amount of the revolving commitment under the LSA from \$75,000,000 to \$85,000,000. The increase in the amount of the revolving commitment was necessary in order to fund the Company s increased working capital requirements primarily as a result of increased sales.

The foregoing summary is qualified in its entirety by reference to the complete text of the Third Amendment to the LSA, a copy of which is attached as Exhibit 10.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits. The following are furnished as exhibits to this Current Report:

Exhibit No. Description of Exhibit

10.1 Third Amendment to the Amended and Restated Loan and Security Agreement

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.

Date: August 14, 2008

BIOSCRIP, INC.

By: /s/ Barry A. Posner  
Barry A. Posner,  
Executive Vice President, Secretary  
and General Counsel